001     301714
005     20250627115808.0
024 7 _ |a 10.1007/s00117-025-01459-5
|2 doi
024 7 _ |a pmid:40434719
|2 pmid
024 7 _ |a 2731-7048
|2 ISSN
024 7 _ |a 0033-832X
|2 ISSN
024 7 _ |a 1432-2102
|2 ISSN
024 7 _ |a 2731-7056
|2 ISSN
037 _ _ |a DKFZ-2025-01106
041 _ _ |a German
082 _ _ |a 610
100 1 _ |a Neelsen, Christian Jan Oliver
|0 P:(DE-He78)2af28acfaad8f466abb166306f9597bd
|b 0
|e First author
|u dkfz
245 _ _ |a Staging and treatment response assessment with radiological and nuclear medicine approaches for non-Hodgkin lymphomas.[Staging und Therapieansprechen mit radiologischen und nuklearmedizinischen Verfahren bei Non-Hodgkin-Lymphomen (NHL)].
260 _ _ |a [Berlin]
|c 2025
|b Springer Medizin Verlag GmbH
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1751018257_5832
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:E010#LA:E060# / Volume 65, pages 508–517, (2025)
520 _ _ |a Non-Hodgkin lymphomas (NHL) represent a heterogeneous group of malignant diseases in which the choice of imaging modality and response criteria strongly depends on histology and clinical context. Selecting the appropriate method is essential for individualized treatment planning.According to the Lugano classification, 18F‑fluorodeoxyglucose positron emission tomography/computed tomography (18F‑FDG PET/CT) is the reference standard for staging and response assessment in 18F-FDG-avid NHL. For other lymphoma subtypes with low or variable 18F-FDG avidity, or in cases where reimbursement by statutory health insurance (GKV) is lacking, contrast-enhanced CT is typically used.This article discusses the new classification systems Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) and Response Evaluation Criteria in Lymphoma (RECIL), as well as specific features of certain lymphoma subtypes and novel imaging approaches such as whole-body MRI and innovative PET tracers.This narrative review does not include a systematic evaluation of sensitivity or specificity data.In 18F-FDG-avid lymphomas 18F‑FDG PET/CT remains the gold standard for precise staging and response assessment.Imaging is essential for tailored therapy planning and monitoring in NHL. As most NHL subtypes are 18FDG-avid, PET/CT is the reference standard. However, contrast-enhanced CT continues to play a significant role, particularly in Germany. New PET tracers and whole-body MRI offer promising approaches but require further studies and standardization.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Computed tomography
|2 Other
650 _ 7 |a Diffuse large B‑cell lymphoma
|2 Other
650 _ 7 |a Positron emission tomography
|2 Other
650 _ 7 |a Response Evaluation Criteria in Lymphoma
|2 Other
650 _ 7 |a Response assessment
|2 Other
700 1 _ |a Mohammad, Ahmad
|0 P:(DE-He78)496f1cb8c66dea4b539e53c1971f2473
|b 1
|e First author
|u dkfz
700 1 _ |a Schlemmer, Heinz-Peter
|0 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
|b 2
|u dkfz
700 1 _ |a Dimitrakopoulou-Strauss, Antonia
|0 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992
|b 3
|u dkfz
700 1 _ |a Sachpekidis, Christos
|0 P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2
|b 4
|e Last author
|u dkfz
773 _ _ |a 10.1007/s00117-025-01459-5
|0 PERI:(DE-600)3120921-X
|p 508–517
|t Die Radiologie
|v 65
|y 2025
|x 2731-7048
909 C O |p VDB
|o oai:inrepo02.dkfz.de:301714
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)2af28acfaad8f466abb166306f9597bd
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)496f1cb8c66dea4b539e53c1971f2473
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2025
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-18
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-18
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-18
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b RADIOLOGIE : 2022
|d 2024-12-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-18
920 2 _ |0 I:(DE-He78)E060-20160331
|k E060
|l E060 KKE Nuklearmedizin
|x 0
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 0
920 1 _ |0 I:(DE-He78)E060-20160331
|k E060
|l E060 KKE Nuklearmedizin
|x 1
920 0 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a I:(DE-He78)E060-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21